Actavis’ $25 Billion Forest Labs Buy Expands Geographic Reach, Product Portfolio
This article was originally published in The Pink Sheet Daily
The merged company will hold blockbuster franchises in CNS, gastroenterology and women’s health, involving generics as well as brands, as well as a large and diversified U.S. sales force and the means to invest more than $1 billion annually in R&D.
You may also be interested in...
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.
Sanofi is paying for $3.68bn cash for Principia to get the US biotech’s drug development platform and nascent pipeline, including a brain-penetrant BTK inhibitor in Phase III for multiple sclerosis.